Hansa’s Q1 result includes a positive outlook in 2024 supported by additional countries and the Eurotransplant program. 75% of the European market is now reimbursed. The US pivotal study CinfIdeS is also making enrolment progress, and randomization is on track for completion by mid-2024. We expect further positive share price support.